SEC Form 10-Q Summary
Filing identity: The provided filing is for Aadi Bioscience, Inc., not Whitehawk Therapeutics, Inc. It covers the unaudited quarter ended March 31, 2022, filed May 12, 2022. Aadi is an early commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers.
Business Context and Reporting Period
Aadi commercialized FYARRO (nab-sirolimus) in the United States on February 22, 2022, following FDA approval in November 2021 for adult patients with locally advanced or metastatic malignant PEComa. The company also initiated enrollment in the PRECISION 1 Phase 2 study for tumors with TSC1 or TSC2 alterations; the first patient was dosed in March 2022.
Key Financial Metrics
| Metric | Three months ended March 31, 2022 | Comparable 2021 period |
|---|---|---|
| Total revenue | $2.307 million | $0.120 million |
| Net product sales | $2.307 million | None |
| Operating expenses | $16.121 million | $4.207 million |
| Loss from operations | $(13.814) million | $(4.087) million |
| Net loss | $(13.857) million | $(5.476) million |
| Basic and diluted loss per share | $(0.66) | $(2.15) |
| Cash used in operating activities | $(19.415) million | Cash provided of $10.563 million |
| Cash and cash equivalents at period end | $129.849 million | $15.018 million |
Product sales were reduced by approximately $0.4 million for distribution fees, rebates, chargebacks, co-payment assistance and product-return provisions. Cost of goods sold was $0.179 million, primarily reflecting royalties and costs related to FYARRO sales. The resulting gross margin was approximately 92%; however, the company remained deeply unprofitable because of commercialization, research and development, and public-company costs.
Selling, general and administrative expense increased to $9.148 million from $0.563 million, driven by increased personnel, commercialization and marketing, consulting, legal, insurance and office costs. Research and development expense increased to $6.794 million from $3.644 million, primarily due to personnel, consulting and external clinical-development costs.
At March 31, 2022, total assets were $142.319 million, total liabilities were $17.691 million and stockholders’ equity was $124.628 million. The company had an accumulated deficit of $156.542 million. There were no convertible promissory notes outstanding. Significant obligations included $5.757 million due to the FYARRO licensor, payable in August 2024 plus accrued interest, and operating lease liabilities of $0.587 million.
Material Changes Versus the Prior Comparable Period
- FYARRO generated $2.307 million of initial quarterly product sales versus no product sales in the prior-year period.
- Total revenue increased from $0.120 million to $2.307 million; grant revenue declined to zero because the relevant FDA grant-reimbursement period had ended.
- Operating expenses increased by $11.914 million, reflecting the commercial launch, expanded staffing, public-company costs and increased clinical-development activity.
- Net loss increased by $8.381 million, while loss per share improved because the post-merger share count was substantially higher.
- Operating cash flow shifted from a $10.563 million inflow to a $19.415 million outflow, primarily because of the net loss and working-capital requirements associated with the commercial launch, including accounts receivable and inventory.
- Cash declined by $19.140 million during the quarter, partly offset by $0.298 million from stock-option and warrant exercises.
Outlook, Commentary, Risks and Unusual Items
- Management stated that available cash was expected to fund planned operations into 2024, although the company expects continuing operating losses and significant additional spending on commercialization and clinical development.
- Aadi entered into an at-the-market sales agreement permitting up to $75.0 million of common-stock sales. No shares had been sold under the agreement as of March 31, 2022.
- Fresenius Kabi became the single-source manufacturer for FYARRO under a 2022 agreement that includes minimum purchase obligations and potential additional payments if minimum quantities are not purchased.
- After quarter-end, Gossamer Bio terminated the legacy Gossamer license agreement effective July 24, 2022. Aadi expected to fully impair the related $3.7 million intangible asset in the second quarter of 2022, and the associated contingent value rights were expected to be cancelled without payment.
- FYARRO remains dependent on regulatory compliance, payer coverage and reimbursement, market acceptance, clinical outcomes for additional indications and continued supply from third-party manufacturers.
- COVID-19 could delay clinical-trial enrollment, site operations, regulatory activities and manufacturing or supply-chain activities. The filing also identifies risks from competition, healthcare-price regulation, intellectual-property protection, reliance on collaborators and future financing needs.
- The company reported no material legal proceedings and stated that its disclosure controls and procedures were effective as of March 31, 2022.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Aadi Bioscience, Inc., while the request identifies Whitehawk Therapeutics, Inc.
- Verify the sustainability and composition of FYARRO sales, including gross-to-net deductions, channel inventory, payer reimbursement and customer concentration.
- Assess cash-burn trends and whether the stated runway into 2024 remains achievable given planned commercialization and clinical-development spending.
- Review the $5.757 million licensor obligation due in 2024, including accrued interest and royalty requirements.
- Monitor the expected $3.7 million impairment related to the terminated Gossamer license and the cancellation of the associated CVRs.
- Evaluate dependence on Fresenius Kabi as the single-source FYARRO manufacturer and the financial impact of minimum-purchase commitments.
- Track PRECISION 1 enrollment, clinical results and regulatory requirements for potential expansion beyond the approved PEComa indication.